EU regulators blast China’s Zhejiang Huahai over valsartan API mess

European Medicines Agency UK
The EMA has taken action against China’s Zhejiang Huahai, the API maker at the heart of a global recall for having sold tainted products. (EMA)

The European Medicines Agency has piled onto China’s Zhejiang Huahai, finding its manufacturing out of compliance for the valsartan API that has been recalled globally after being found to contain a suspected carcinogen.

The action was posted Friday, the same day the FDA announced it has finally put the Chinese company on import alert, meaning it products are now banned from the U.S. The company primarily makes APIs and intermediates for of valsartan, which is used to make blood pressure drugs. 

A September inspection by the Italian Medicines Agency found essentially the same issues laid out in an FDA Form 483: that Huahai did not carefully evaluate the risks of changes to its manufacturing processes that led to the formation of the impurity. N-nitrosodimethylamine, a suspected cancer-causing agent, was discovered in Huahai’s APIs this summer.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

When out-of-spec results were found by Huahai, it explained the results away and shipped products anyway. EU regulators said nine “Major” and eight “Other” deviations were identified.

The discovery has led to a global recall of more than half of all valsartan products on the market (PDF). The FDA said patients can still find untainted products (PDF) from other producers. While the levels of NDMA in ZHP’s valsartan API were trace amounts, they were considered unacceptable, the FDA has said.

The report said the joint inspection by the EMA and the European Directorate for the Quality of Medicines (EDQM) “was initiated as for-cause inspection in the context of the NDMA/NDEA Valsartan contamination issue. Nine “Major” and eight “Other” deviations were identified.”

It said Huahai’s APIs have already been banned from the EU, but that countries should consider banning its intermediates as well.

After the initial recall, the FDA started looking into the chemical class of “genotoxic impurities,” into which valsartan falls, and recently said it uncovered a second and unexpected cancer-causing impurity in three batches of the blood pressure medicine valsartan that were sold by Torrent Pharmaceuticals. The regulatory agency said the newest impurity to be found was N-Nitrosodiethylamine (NDEA), which is a known animal and suspected human carcinogen. The products tested were included in Torrent’s recall last month.

Suggested Articles

Three facts about how distributors are managing in-demand inventory.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.

Purdue has reached an $8 billion settlement with the U.S. government to settle criminal and civil charges for its role in the U.S. opioid crisis.